AllSci News
FDA Approves GSK's Arexvy for At-Risk Adults Aged 18–49 Against RSV Disease
The US FDA has approved an expanded age indication for Arexvy (respiratory syncytial virus vaccine, adjuvanted), GSK's recombinant protein-based RSV...
Bayer's finerenone meets primary endpoint in Phase III non-diabetic chronic kidney disease study
Bayer announced that finerenone (KERENDIA) met the primary endpoint of its Phase III FIND-CKD study in patients with non-diabetic chronic kidney disease,...
Vima Therapeutics Extends Series A to USD 100 Million, Begins Dosing Dystonia Phase 2 Trial
Cambridge, Massachusetts-based Vima Therapeutics, a clinical-stage company developing oral therapies for movement disorders, has extended its Series A...
Formosa Pharmaceuticals licenses clobetasol propionate ophthalmic suspension to Arrotex for Australia and New Zealand
Taiwan-headquartered Formosa Pharmaceuticals (6838.TW) announced an exclusive licensing agreement with Arrotex Pharmaceuticals Pty Ltd, an Australian...
Alteogen licenses ALT-B4 hyaluronidase technology to Biogen in USD 579m. subcutaneous biologics deal
Alteogen, a South Korea-based biopharmaceutical company headquartered in Daejeon, has entered into an exclusive Alteogen Biogen license agreement granting...
MeiraGTx's AAV2-hAQP1 gene therapy earns FDA breakthrough designation for radiation-induced xerostomia
MeiraGTx Holdings plc (Nasdaq: MGTX), a clinical-stage genetic medicines company headquartered in London and New York, announced that the FDA has granted...
Iterion Therapeutics doses first patient with tegavivint in metastatic colorectal cancer Phase I/II trial
Iterion Therapeutics, a Houston-based clinical-stage oncology company, announced that the first patient has been dosed in a Phase I/II clinical trial...
FDA approves Corcept Therapeutics' Lifyorli for platinum-resistant ovarian cancer
The US FDA on March 25, 2026, approved Lifyorli (relacorilant) in combination with nab-paclitaxel for the treatment of adults with platinum-resistant...
Helsinn Healthcare and InVirtuoLabs Partner on AI-Driven Small-Molecule Drug Discovery Collaboration
Helsinn Healthcare SA, the privately held Swiss pharmaceutical group, and In Virtuo Laboratories SA (InVirtuoLabs), a Lugano-based biotech startup...
Insilico Medicine and ASKA Pharmaceutical partner on AI-driven target discovery for gynecological diseases
Insilico Medicine and ASKA Pharmaceutical have entered a research collaboration to identify novel therapeutic targets for gynecological conditions including...
Remix Therapeutics' REM-422 Earns FDA Fast Track Designation for Adenoid Cystic Carcinoma Treatment
Remix Therapeutics, a clinical-stage biotechnology company headquartered in Watertown, Massachusetts, announced that the US FDA has granted Fast Track...
Coherus Oncology raises USD 50.1m in public offering of common stock
Redwood City, California-based Coherus Oncology, Inc. (NASDAQ: CHRS) announced the pricing of an underwritten Coherus Oncology public offering of common...
Aldeyra Therapeutics receives CRL for reproxalap citing lack of efficacy in dry eye disease
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) disclosed that the U.S. Food and Drug Administration issued a Complete Response Letter for the New Drug...
Yatiri Bio options global rights to Oscotec's multikinase inhibitor denfivontinib for AML
Yatiri Bio, a San Diego-based precision medicine company, has entered an exclusive global option to in-license agreement with South Korea's Oscotec for...
Shionogi Acquires Apnimed's SASS Joint Venture Stake for USD 150m to Consolidate Sleep Medicine Portfolio
Shionogi & Co., Ltd. has entered a definitive agreement to acquire Apnimed, Inc.'s 50% ownership of the Shionogi-Apnimed Sleep Science, LLC (SASS) joint...
The AllSci Brief
Systematic R&D and deal news. Daily.